During the Second International Conference on Influenza Vaccines for the World (IVW), held October 18-20, 2006 in Vienna, Austria, Yawei Ni, Ph.D., Senior Scientist at DelSite Biotechnologies, gave an oral presentation entitled "An Inactivated Influenza Nasal Powder Vaccine", as announced by Carrington Laboratories, Inc. (Nasdaq: CARN).
The said presentation described an influenza nasal powder vaccine that incorporates inactivated whole virion antigen in the GelVac™ dry powder delivery system, a unique in situ gelling powder formulation. Once hydrated by nasal fluid, the GelVac™ powder formulation changes from dry powder particles to wet gel particles, resulting in the formation of a gel that adheres to nasal mucus, thereby maximizing antigen exposure through prolonged nasal residence time and sustained antigen release. Find more details from the press release.
Comment Preview